Pacira Pharmaceuticals (PCRX): Price-to-Sales Ratio

Symbol and logo of brand Pacira (PCRX)

The industry-average P/S of Pacira BioSciences (PCRX) reflects the adoption dynamics of EXPAREL into US hospital standards as an opioid substitute. Competent management effectively protects intellectual property, minimizing legal risks. Optimized temperature-controlled hubs guarantee supply stability. The value of 2.00 captures the current state of the parameter, helping to determine the degree of overpayment for the asset relative to its revenue.

P/S Multiple: Pacira BioSciences, Inc. (PCRX) for 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Pacira (PCRX)

- share price and consensus valuation forecast:
Price Performance Chart pacira.com|PCRX - Price Target Chart
- stock exchange capitalization data:
Market Valuation Pacira|PCRX - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Pacira BioSciences|PCRX - Book Capitalization|Market Cap to Net Assets Ratio pacira.com|PCRX - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Pacira BioSciences|PCRX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Pacira Corp|PCRX - Company Aggregate Debts|Debts to Book Capitalization Pacira|PCRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Pacira BioSciences|Quick Liquidity pacira.com
- company profitability and valuation multiples indicators:
PCRX - Net Profit|Company Profit Forecast Pacira BioSciences|PCRX - Price to Earnings Ratio|Projected Price to Earnings Ratio Pacira Pharmaceuticals|PCRX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Pacira|PCRX - Operating profit EBITDA|Net earnings per share for the last 12 months Pacira BioSciences|PCRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months pacira.com|PCRX - Earnings growth in current year|Expected net earnings per share growth next year Pacira BioSciences
- issuer revenue and sales details:
PCRX - Company Revenue|Company Revenue Forecast pacira.com|PCRX - P/S Multiple|Forward Price-to-Revenue Multiple Pacira
General company analysis:PCRX pacira.com
Core merchandise of Pacira Corp

The risk of overpaying for the asset is minimized through a daily comparative analysis of market capitalization and actual sales volume, rendering the P/S multiple an operational monitoring tool for business valuation between quarterly reports. For Pacira BioSciences (PCRX), this chart reflects the effectiveness of its expansion into the non-opioid pain management segment, allowing investors to assess the extent to which market expectations regarding patent protection and the management's scientific strategy align with current revenue.

Who Pacira BioSciences competes with

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|Jyong Biotech Corp - P/S Multiple|LGND - P/S Multiple|AMRX: P/S Multiple|Market Cap to Revenue perrigo.com|ALVO (Alvotech SA) - P/S Multiple|Liquidia Corp (LQDA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP (ANI Pharmaceuticals Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple MNKD (MannKind Corporation)|P/S Multiple amphastar.com AMPH|SPRY: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TBPH (Theravance Biopharma Inc)|AQST: P/S Multiple|SCPH (scPharmaceuticals) - Price-to-Revenue Ratio|TECX (Tectonic Therapeutic Inc.) - P/S Multiple|tonixpharma.com (TNXP) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio China SXT Pharmaceuticals (SXTC)|EPRX - Price to Sales|Price-to-Revenue Ratio BioHarvest BHST|Price-to-Revenue Coefficient Invizyne (EXOZ)|Oramed Pharma - P/S Multiple|Entera Bio Ltd. (ENTX) - Market Cap to Revenue|HYFT: P/S Multiple|ABVC - Price-to-Revenue Coefficient|CPIX (Cumberland Pharma) - P/S Multiple|Price to Sales Quantum BioPharma Corp QNTM|Price-to-Revenue Ratio FibroGen, Inc. (FGEN)|telomirpharma.com - Market Cap to Revenue Ratio|P/S Multiple RANI (Rani Therapeutics Holdings, Inc.)|SNYR - Market Cap to Revenue|Rallybio Corp. - P/S Multiple|Price to Sales Lexaria Bioscience|Pulmatrix, Inc. (PULM) - Price-to-Revenue Ratio|PTHL - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Aptorum Group Ltd|Lyra Therapeutics Inc. - Price-to-Sales Ratio|P/S Multiple IBO|Market Cap to Revenue tnfpharma.com TNFA|Price-to-Revenue Ratio cbdMD YCBD|Market Capitalization-to-Revenue Ratio PRFX|CYTO: Market Cap to Revenue|LIPO (Lipella Pharmaceuticals Inc) - Market Cap to Revenue Ratio|Optinose (OPTN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PIRS (Pieris Pharma)|PROC (Procaps Group S.A.) - P/S Multiple|PTPI: Market Capitalization-to-Revenue Ratio|P/S Multiple QLI|P/S Multiple Acelyrin Inc. (SLRN)|Price-to-Revenue Ratio TFF Pharma TFFP